<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05119907</url>
  </required_header>
  <id_info>
    <org_study_id>EVER-132-003</org_study_id>
    <nct_id>NCT05119907</nct_id>
  </id_info>
  <brief_title>Sacituzumab Govitecan in Patients With Solid Tumor</brief_title>
  <official_title>A Phase II Open Label Study of Sacituzumab Govitecan in Patients With Solid Tumor</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Everest Medicines</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Everest Medicines</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the efficacy of sacituzumab govitecan in patients&#xD;
      with unresectable, locally advanced or metastatic solid tumor&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">September 23, 2021</start_date>
  <completion_date type="Anticipated">December 2025</completion_date>
  <primary_completion_date type="Anticipated">November 2022</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>ORR according to Response Evaluation Criteria in Solid Tumors version 1.1 (RECIST v 1.1) by investigator assessment</measure>
    <time_frame>4 years</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Other efficacy parameters: Duration of response, disease control rate (DCR), progression-free survival (PFS), overall survival (OS)</measure>
    <time_frame>4 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety and tolerability (AEs, serious adverse events [SAEs] according to National Cancer Institute-Common Terminology Criteria for Adverse Events version 5.0 [NCI-CTCAE v 5.0])</measure>
    <time_frame>4 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PK parameters (AUC0-168h, Cmax, T1/2) and ADA</measure>
    <time_frame>4 years</time_frame>
  </secondary_outcome>
  <other_outcome>
    <measure>Tumor tissue biomarker (Trop-2 expression)</measure>
    <time_frame>4 years</time_frame>
  </other_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">180</enrollment>
  <condition>Solid Tumor</condition>
  <arm_group>
    <arm_group_label>oesophageal squamous-cell carcinoma</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>gastric adenocarcinoma</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>cervical cancer</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Sacituzumab Govitecan-hziy</intervention_name>
    <description>10 mg/kg intravenously on Days 1 and 8 of a 21-day cycle. Number of Cycles: until disease progression or intolerable toxicity or consent withdrawal for any reason.</description>
    <arm_group_label>cervical cancer</arm_group_label>
    <arm_group_label>gastric adenocarcinoma</arm_group_label>
    <arm_group_label>oesophageal squamous-cell carcinoma</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Male or female adult, 18 years of age or older providing written informed consent.&#xD;
&#xD;
          -  Eastern Cooperative Oncology Group (ECOG) performance status (PS) of 0 or 1.&#xD;
&#xD;
          -  Histologically or cytologically-documented, incurable locally advanced or metastatic&#xD;
             solid tumor of one of the following types:&#xD;
&#xD;
          -  Cohort A: oesophageal squamous-cell carcinoma that was refractory or intolerant to&#xD;
             fluoropyrimidine-based, platinum-based, and taxane-based chemotherapy.&#xD;
&#xD;
          -  Cohort B: gastric adenocarcinoma that was refractory or intolerant to&#xD;
             fluoropyrimidine-based, platinum-based, and taxane-based chemotherapy.&#xD;
&#xD;
          -  Cohort C: cervical cancer that was refractory or intolerant to platinum-based and&#xD;
             taxane-based chemotherapy.&#xD;
&#xD;
          -  Measurable disease by computed tomography (CT) or magnetic resonance imaging (MRI) in&#xD;
             accordance with RECIST v 1.1, bone-only disease is not measurable and is not&#xD;
             permitted.&#xD;
&#xD;
          -  Availability of archival tumor tissue or newly acquired biopsy (unstaining tumor&#xD;
             slides, recommended from metastasis sites).&#xD;
&#xD;
          -  Adequate bone marrow, hepatic and renal function.&#xD;
&#xD;
          -  Recovered from all prior treatment-related toxicities to Grade 1 or less by NCI-CTCAE&#xD;
             v 5.0 (except alopecia or peripheral neuropathy that may be Grade 2 or less).&#xD;
&#xD;
          -  Patients must have completed all prior cancer treatments at least 2 weeks prior to the&#xD;
             first dose including chemotherapy , radiotherapy and major surgery. Prior antibody&#xD;
             treatment for cancer must have been completed at least 3 weeks prior to the first&#xD;
             dose.&#xD;
&#xD;
          -  Patients must have at least a 3-month life expectancy&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Previous treatment with topoisomerase I inhibitors as a free form or as other&#xD;
             formulations.&#xD;
&#xD;
          -  Previous treatment with Trop-2 targeted therapy.&#xD;
&#xD;
          -  Patients with a history of or current central nervous system (CNS) metastases. A scan&#xD;
             to confirm the absence of brain metastases is not required. Patients with unknown CNS&#xD;
             metastatic status and any clinical signs indicative of CNS metastases are eligible if&#xD;
             CNS metastases are excluded using CT and/or MRI scans.&#xD;
&#xD;
          -  Known additional malignancy within 3 years prior to enrollment with the exception of&#xD;
             curatively treated basal cell carcinoma of the skin, squamous cell carcinoma of the&#xD;
             skin and/or curatively resected in situ cancers.&#xD;
&#xD;
          -  Patients known to be human immunodeficiency virus positive.&#xD;
&#xD;
          -  Patients with active hepatitis B virus (HBV), or hepatitis C virus (HCV) infection.&#xD;
             Hepatitis B core antibody (HBcAb) testing is required and if positive, then HBV DNA&#xD;
             testing will be performed and if positive the patient will be excluded.&#xD;
&#xD;
          -  Known history of unstable angina, myocardial infarction (MI), or chronic heart failure&#xD;
             present within 6 months of first dose or clinically significant cardiac arrhythmia&#xD;
             (other than stable atrial fibrillation) requiring anti-arrhythmia therapy or left&#xD;
             ventricular ejection fraction &lt; 50%.&#xD;
&#xD;
          -  Known history of clinically significant active chronic obstructive pulmonary disease,&#xD;
             or other moderate-to-severe chronic respiratory illness present within 6 months of the&#xD;
             first dose.&#xD;
&#xD;
        Patients with active chronic inflammatory bowel disease (ulcerative colitis, Crohn disease)&#xD;
        and patients with a history of bowel obstruction or gastrointestinal (GI) perforation.&#xD;
&#xD;
          -  Infection requiring systematic antibiotic use within 1 week of the first dose.&#xD;
&#xD;
          -  High dose systemic corticosteroids within 2 weeks prior to the first dose (however,&#xD;
             low dose corticosteroids â‰¤ 10 mg prednisone or equivalent daily are permitted provided&#xD;
             the dose is stable for 4 weeks).&#xD;
&#xD;
          -  Patients who have received a live vaccine within 30 days of first dose.&#xD;
&#xD;
          -  Rapid deterioration during Screening prior to the first dose, eg, significant change&#xD;
             in PS, substantial increase in hydrothorax, unstable pain symptoms requiring&#xD;
             modifications in analgesic management.&#xD;
&#xD;
          -  Other concurrent medical or psychiatric conditions that, in the Investigator's&#xD;
             opinion, may be likely to confound study interpretation or prevent completion of study&#xD;
             procedures and follow-up examinations.&#xD;
&#xD;
          -  Women who are pregnant or lactating.&#xD;
&#xD;
          -  Women of childbearing potential or fertile men unwilling to use highly effective&#xD;
             contraception during study and up to 6 months after treatment discontinuation in women&#xD;
             of childbearing potential and 3 months in males post last investigational product (IP)&#xD;
             administration.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Beijing Cancer Hospital</name>
      <address>
        <city>Beijing</city>
        <state>Beijing</state>
        <zip>100142</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Lin Shen, Ph.D</last_name>
      <phone>010-88196561</phone>
      <email>linshenpku@163.com</email>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>November 2021</verification_date>
  <study_first_submitted>November 3, 2021</study_first_submitted>
  <study_first_submitted_qc>November 3, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">November 15, 2021</study_first_posted>
  <last_update_submitted>November 3, 2021</last_update_submitted>
  <last_update_submitted_qc>November 3, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 15, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neoplasms</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

